MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ
1.191
-0.299
-20.08%
Opening 14:52 04/01 EDT
OPEN
1.330
PREV CLOSE
1.490
HIGH
1.330
LOW
1.180
VOLUME
594.97K
TURNOVER
--
52 WEEK HIGH
26.75
52 WEEK LOW
1.180
MARKET CAP
10.23M
P/E (TTM)
-0.2051
1D
5D
1M
3M
1Y
5Y
1D
Citius Pharmaceuticals stock plummets on $2M registered direct offering of common stock
Seeking Alpha · 5h ago
CITIUS PHARMACEUTICALS ANNOUNCES $2 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK
Reuters · 5h ago
Weekly Report: what happened at CTXR last week (0324-0328)?
Weekly Report · 1d ago
Weekly Report: what happened at CTXR last week (0317-0321)?
Weekly Report · 03/24 11:42
Weekly Report: what happened at CTXR last week (0310-0314)?
Weekly Report · 03/17 11:54
Weekly Report: what happened at CTXR last week (0303-0307)?
Weekly Report · 03/10 11:56
Weekly Report: what happened at CTXR last week (0224-0228)?
Weekly Report · 03/03 11:55
Citius Pharma Advances LYMPHIR Launch Amid Financial Updates
TipRanks · 02/25 03:52
More
About CTXR
More
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Recently
Symbol
Price
%Change

Webull offers Citius Pharmaceuticals Inc stock information, including NASDAQ: CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.